Signal
Celcuity’s gedatolisib shows positive phase 3 results in breast cancer, advancing FDA filings
Evidence first: scan the strongest sources, then decide whether to go deeper.
redditrss
clinical_trialsfdadrug_developmentbiotech_fundingr_and_dsafety_signals
Trend in the last 24h
Current brief openSource links open
This current signal is open on the public brief with summary, metadata, source links, and full evidence. Pro adds compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Celcuity’s pan-PI3K/mTOR inhibitor gedatolisib has met the primary endpoint in a phase 3 trial (Viktoria-1) for HR+ metastatic breast cancer, demonstrating significantly longer progression-free survival compared to Novartis’ Piqray in PIK3CA-mutant patients.
Entities
CelcuityNovartisAstraZenecaPfizerViktoria-1
Score total
1.52
Momentum 24h
3
Posts
3
Origins
3
Source types
2
Duplicate ratio
0%
Why now
- FDA decision on initial application expected by July 17, 2026, making recent data timely for regulatory filings.
- Upcoming ASCO 2026 meeting provides a platform to showcase new clinical data to the oncology community.
- Competition with established PI3K inhibitors like Piqray highlights the importance of demonstrating clinical benefit in phase 3 trials.
Why it matters
- Positive phase 3 results increase chances of FDA approval for a new breast cancer therapy.
- Demonstrated superiority over existing treatment (Piqray) could shift clinical practice for HR+ metastatic breast cancer.
- Broader approval could expand treatment options for patients with both PIK3CA-mutant and wild-type tumors.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: medium
Recurring claims
- Celcuity’s pan-PI3K/mTOR inhibitor gedatolisib met the primary endpoint in a phase 3 trial for HR+ metastatic breast cancer with PIK3CA mutations.
- Gedatolisib showed significantly longer progression-free survival compared to Novartis’ Piqray in the Viktoria-1 trial.
- The positive trial results support a second FDA submission for gedatolisib, which is already under review for PIK3CA-wild-type breast cancer with a decision expected by July 17, 2026.
- New data from the trial strengthen Celcuity’s case for broader approval and will be presented at ASCO 2026.
How sources frame it
- Fierce Biotech: neutral
- Reddit Biotech Community: neutral
- BioPharma Dive: neutral
Consolidated multiple reports on Celcuity’s phase 3 breast cancer trial results and regulatory progress into a clear narrative highlighting clinical and regulatory milestones.
All evidence
All evidence
Fierce Biotech report on Celcuity’s phase 3 trial success
fiercebiotech.com · fiercebiotech.com · 2026-05-04 12:08 UTC
BioPharma Dive coverage on Celcuity’s ASCO plans and approval strategy
biopharmadive.com · biopharmadive.com · 2026-05-04 16:23 UTC
Reddit biotech discussion on Viktoria-1 trial results (via Reddit)
reddit.com · reddit.com · 2026-05-04 13:15 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 3Duplicates: -
Showing 3 / 0
Top publishers (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)
- reddit.com (1)
Top origin domains (this list)
- fiercebiotech.com (1)
- biopharmadive.com (1)
- reddit.com (1)